Drug intelligence / Profile preview

Treg-depleted donor lymphocyte infusion

Development stage
Phase 2
Lead developer
Assistance publique - Hôpitaux de Paris
Modality
Cell Therapies
Administration
Intravenous
01

Overview

Treg-depleted donor lymphocyte infusion (DLI) is an adoptive cellular immunotherapy developed by Assistance Publique - Hôpitaux de Paris for the treatment of relapsed hematological malignancies following allogeneic hematopoietic stem cell transplantation (HSCT). The therapy involves the infusion of donor lymphocytes from which regulatory T cells (Tregs) have been selectively removed. Tregs are known to suppress anti-tumor immune responses; by depleting them, the graft-versus-leukemia (GVL) effect of the donor T cells is enhanced. While earlier strategies targeted CD25 for depletion, this specific approach utilizes CD127 (interleukin-7 receptor alpha) positive selection to more effectively isolate and remove the Treg population, thereby amplifying the allogeneic immune response against malignant cells.

Other names
Regulatory T cell-depleted donor lymphocyte infusionCD127-selected Treg-depleted DLICD-127-selected Treg-depleted DLICD 127-selected Treg-depleted DLI

Beyond the preview

Go deeper on Treg-depleted donor lymphocyte infusion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Treg-depleted donor lymphocyte infusion.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call